Tormere Analytics
OverviewStock ResearchChartsPortfolio LabOptions LabCalculatorsWatchlist
Data Explorer
Articles
Pricing
Privacy PolicyTerms of Service

SPRY

$4.07-1.21%website ↗⬇ financials (.py)

ARS Pharmaceuticals, Inc.

Market Cap
$404M
Live price × shares (2026-09-17)
Sector
Health Care
Industry
Biotechnology
Beta (raw)
0.83
60mo monthly vs SPY
P/E (TTM)
N/M
Price / TTM net income
P/S (TTM)
3.5
Price / TTM revenue
P/B
32.3
Price / stockholders equity
EV/EBITDA
—
TTM
Price Chart
Loading…

Signals

Insider Velocity
0.2x
selling
Congress
—
recent trades
Short Volume
70%
W/W +4.0pp

Market & Alt Data

News
15
recent articles
Activist
13D
RA
Analyst Consensus
Strong Buy
10 analysts
Velocity Score
0.18x
Sell Rate (90d)
315.06/mo
Sell Baseline
4370.85/mo
Unique Sellers (90d)
2
Sort by
Type
Trade DateFiledOwnerRoleTypeSharesPriceValueOwned After
2026-06-122026-06-12Fitzpatrick Alexander AChief Legal OfficerSale3,355$10.00$34K90.9KView
2026-06-122026-06-12Karas EricChief Commercial OfficerSale25.0K$10.00$250K12.2KView
2025-11-132025-11-14Dorsey BrianChief Operating OfficerSale21.8K$8.71$190K10.8KView
2025-11-122025-11-14Chakma JustinChief Business OfficerSale166.4K$8.87$1.48M0View
2025-08-212025-08-22Scott Kathleen D.Chief Financial OfficerSale12.5K$15.00$188K10.0KView
1–5 of 11
1 / 3

Reporting Insiders

  • Alexander A. Fitzpatrick
    Chief Legal Officer
    1 transaction · last 2026-06-12
  • Eric Karas
    Chief Commercial Officer
    3 transactions · last 2026-06-12
  • Brian Dorsey
    Chief Operating Officer
    1 transaction · last 2025-11-13
  • Justin Chakma
    Chief Business Officer
    2 transactions · last 2025-11-12
  • Kathleen D. Scott
    Chief Financial Officer
    1 transaction · last 2025-08-21
  • Richard E. Lowenthal
    Director & PRESIDENT AND CEO
    1 transaction · last 2025-08-21
  • Sarina Tanimoto
    CHIEF MEDICAL OFFICER
    2 transactions · last 2025-08-20

Gov Contracts

AgencyAmountAwarded
Department of Defense$5.0B2009-03-19
Department of Transportation$1.5B2012-08-23
Department of Defense$1.2B2021-07-16

Recent News

Officer Eric Karas proposes selling 100,000 shares of ARS Pharmaceuticals (SPRY).
Stock Titan · 2026-10-01
SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
Morningstar · 2026-10-01
Eric Karas proposes selling 100,000 ARS Pharmaceuticals (SPRY) shares after a $69.8K September sale.
Stock Titan · 2026-09-30
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY
Morningstar · 2026-09-30
Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's Success
SeekingAlpha · 2026-09-30
SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice - Contact Levi & Korsinsky
PR Newswire · 2026-09-23
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
Yahoo Finance · 2026-09-01
ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share
Yahoo Finance · 2026-08-21
ARS Pharma (SPRY) Q2 2026 Earnings Call Transcript
Yahoo Finance · 2026-08-20
Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?
Yahoo Finance · 2026-08-20
ARS Pharmaceuticals (SPRY) Stock Faces Margin Squeeze As Losses Deepen
Simply Wall Street · 2026-08-15
ARS Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Yahoo Finance · 2026-08-14
ARS Pharmaceuticals Q2 Earnings Call Highlights
Yahoo Finance · 2026-08-14
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
Yahoo Finance · 2026-08-13
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates
Yahoo Finance · 2026-08-13

Informational purposes only, not investment advice.

ARS Pharmaceuticals, Inc. (SPRY)

tormere.com/research/SPRY · generated 2026-10-04

$4.07
-1.21%
General Information
Price$4.07
Change-1.21%
Market Cap$404M
SectorHealth Care
IndustryBiotechnology
ExchangeNasdaq
Beta (raw, 60mo vs SPY)0.83
Signals
Insider Velocity0.2x selling
Congress Trades—
  • Flynn James E
    10% Owner
    2 transactions · last 2025-06-27
    • Short Volume
    70% of daily vol
    Conviction Score23/100
    Analyst ConsensusSB 5 · B 4 · H 1 · S 0 · SS 0
    Price Chart (1 Year)
    2025-10-062026-10-02$13.06$4.07
    Recent Insider Activity (Form 4) — Last 5
    DateInsiderTypeSharesValue
    2026-06-12Fitzpatrick Alexander AS3,355$33,550
    2026-06-12Karas EricS25,000$250,000
    2025-11-13Dorsey BrianS21,828$190,049.85
    2025-11-12Chakma JustinS30,000$267,357
    2025-11-12Chakma JustinS136,380$1M
    Recent News
    • Officer Eric Karas proposes selling 100,000 shares of ARS Pharmaceuticals (SPRY). — Stock Titan · 2026-10-01
    • SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026 — Morningstar · 2026-10-01
    • Eric Karas proposes selling 100,000 ARS Pharmaceuticals (SPRY) shares after a $69.8K September sale. — Stock Titan · 2026-09-30
    • Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY — Morningstar · 2026-09-30
    • Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's Success — SeekingAlpha · 2026-09-30

    Tormere — informational purposes only, not investment advice.

    Factor Profile

    Pro
    Pro feature

    Fama-French factor analysis is available on the Pro plan.

    Upgrade to Pro →
    Pipeline
    Phase 4
    2 active trials · readout 2027-04